Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Long-term Extension Study of PCI-32765 (Ibrutinib)
Sponsor: Janssen Research & Development, LLC
Summary
The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to ibrutinib for participants who are currently enrolled in ibrutinib studies that have been completed according to the parent protocol, are actively receiving treatment with ibrutinib, and who continue to benefit from ibrutinib treatment.
Official title: PCI-32765CAN3001: A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
539
Start Date
2013-09-09
Completion Date
2029-12-31
Last Updated
2026-11-03
Healthy Volunteers
No
Conditions
Interventions
Ibrutinib
Ibrutinib will be given orally as capsules, once daily continuously, according to the current dosing regimen established in the parent ibrutinib clinical study (560 mg, 420 mg, 280 mg, or 140 mg), at approximately the same time each day.
Locations (156)
Duarte, California, United States
La Jolla, California, United States
Los Angeles, California, United States
Orange, California, United States
Stanford, California, United States
Norwalk, Connecticut, United States
Marietta, Georgia, United States
Chicago, Illinois, United States
Goshen, Indiana, United States
Westwood, Kansas, United States
Louisville, Kentucky, United States
Boston, Massachusetts, United States
Ann Arbor, Michigan, United States
Battle Creek, Michigan, United States
Detroit, Michigan, United States
St Louis, Missouri, United States
Lebanon, New Hampshire, United States
Hackensack, New Jersey, United States
New York, New York, United States
Goldsboro, North Carolina, United States
Columbus, Ohio, United States
Eugene, Oregon, United States
Portland, Oregon, United States
Philadelphia, Pennsylvania, United States
Sioux Falls, South Dakota, United States
Houston, Texas, United States
Charlottesville, Virginia, United States
Seattle, Washington, United States
Morgantown, West Virginia, United States
Madison, Wisconsin, United States
Ciudad Autonoma Buenos Aires, Argentina
Ciudad de Buenos Aires, Argentina
Adelaide, Australia
Coburg, Australia
Concord, Australia
Heidelberg, Australia
Melbourne, Australia
Perth, Australia
Prahran, Australia
Wahroonga, Australia
Antwerp, Belgium
Bruges, Belgium
Brussels, Belgium
Ghent, Belgium
Leuven, Belgium
Yvoir, Belgium
Rio de Janeiro, Brazil
Salvador, Brazil
São Paulo, Brazil
Montreal, Quebec, Canada
Beijing, China
Chengdu, China
Fuzhou, China
Guangzhou, China
Hangzhou, China
Shanghai, China
Shanxi, China
Suzhou, China
Tianjin, China
Wuhan, China
Bogotá, Colombia
Floridablanca, Colombia
Brno, Czechia
Prague, Czechia
Créteil, France
Mulhouse, France
Paris, France
Pessac, France
Pierre-Bénite, France
Tours, France
Berlin, Germany
Dresden, Germany
Essen, Germany
Giessen, Germany
Heidelberg, Germany
Homburg/Saar, Germany
Magdeburg, Germany
Marburg, Germany
Ulm, Germany
Athens, Greece
Thessalonikis, Greece
Budapest, Hungary
Szeged, Hungary
Dublin, Ireland
Afula, Israel
Hadera, Israel
Haifa, Israel
Petah Tikva, Israel
Ramat Gan, Israel
Tel Aviv, Israel
Bunkyō City, Japan
Hiroshima, Japan
Oaxaca City, Mexico
Amsterdam, Netherlands
Brzozów, Poland
Chorzów, Poland
Gdansk, Poland
Klinika Nowotworow Ukladu Chlonnego, Poland
Krakow, Poland
Opole, Poland